Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Viridian Therapeutics Inc
(NQ:
VRDN
)
12.88
+0.18 (+1.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Viridian Therapeutics Inc
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
December 18, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
November 08, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
November 03, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
October 30, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
October 26, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
September 25, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
September 07, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 04, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
July 10, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 06, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
June 13, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease
August 15, 2022
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is engaged as a biotechnology company, which is focused on the research and development of
Via
Spotlight Growth
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.